Successful eradication of established peritoneal ovarian tumors in SCID-Beige mice following adoptive transfer of T cells genetically targeted to the MUC16 antigen. - Wikidata - awgldk - TriplyDB

Successful eradication of established peritoneal ovarian tumors in SCID-Beige mice following adoptive transfer of T cells genetically targeted to the MUC16 antigen.

Successful eradication of established peritoneal ovarian tumors in SCID-Beige mice following adoptive transfer of T cells genetically targeted to the MUC16 antigen.

http://www.wikidata.org/entity/Q34007762

about

Chimeric antigen receptor T-cell therapy for solid tumors Immunotherapy: New Strategies for the Treatment of Gynecologic Malignancies Chimeric Antigen Receptors Modified T-Cells for Cancer Therapy Overview of current immunotherapeutic strategies for glioma Strategies and Advancements in Harnessing the Immune System for Gastric Cancer Immunotherapy Antibody, T-cell and dendritic cell immunotherapy for malignant brain tumors Strategies to genetically engineer T cells for cancer immunotherapy.Emerging immunotherapeutics in adenocarcinomas: A focus on CAR-T cells CAR-modified T-cell therapy for cancer: an updated review.Driving CAR T-cells forward Chimeric antigen receptors for T cell immunotherapy: current understanding and future directions Genetically engineered T cells for the treatment of cancer.Past, present and future targets for immunotherapy in ovarian cancer IL-12 secreting tumor-targeted chimeric antigen receptor T cells eradicate ovarian tumors in vivo.Optimizing molecular-targeted therapies in ovarian cancer: the renewed surge of interest in ovarian cancer biomarkers and cell signaling pathways.L1 Cell Adhesion Molecule-Specific Chimeric Antigen Receptor-Redirected Human T Cells Exhibit Specific and Efficient Antitumor Activity against Human Ovarian Cancer in Mice Immunotherapy of malignant disease using chimeric antigen receptor engrafted T cells Opportunities in immunotherapy of ovarian cancer.Leveraging immunotherapy for the treatment of gynecologic cancers in the era of precision medicine Cancer Precision Medicine in China.Recent technological advances in using mouse models to study ovarian cancer.Dual mTORC1/2 Inhibition as a Novel Strategy for the Resensitization and Treatment of Platinum-Resistant Ovarian Cancer Adoptive immunotherapy for cancer.Engineering CAR-T cells: Design concepts.Understanding the Unique Attributes of MUC16 (CA125): Potential Implications in Targeted Therapy.Cellular immunotherapy of cancer: an overview and future directions.Adoptive T-Cell Therapy for Solid Tumors.Enhancement of PSMA-Directed CAR Adoptive Immunotherapy by PD-1/PD-L1 Blockade.Optimized T-cell receptor-mimic chimeric antigen receptor T cells directed toward the intracellular Wilms Tumor 1 antigen.Armored CAR T cells enhance antitumor efficacy and overcome the tumor microenvironment.CAR-T cell therapy in ovarian cancer: from the bench to the bedside.Identification of unique neoantigen qualities in long-term survivors of pancreatic cancer.Reprogramming T-cells for adoptive immunotherapy of ovarian cancer.Peritoneal dissemination of ovarian cancer: role of MUC16-mesothelin interaction and implications for treatment.Pancreatic cancer: Next-generation algorithms for neoantigen selection.Chimeric antigen receptor transduced T cells: Tuning up for the next generation.Are ovarian cancer stem cells the target for innovative immunotherapy?Engineered Tumor-Targeted T Cells Mediate Enhanced Anti-Tumor Efficacy Both Directly and through Activation of the Endogenous Immune System.Synthetic immunology: T-cell engineering and adoptive immunotherapy

P2860

Q26750908-803C1633-66C4-427A-8F6D-EF5E7C2269AE Q26770607-0C3FB6C9-9C99-455E-84EB-3EE4DED0C376 Q26773309-86E03ADD-CD4A-4CEC-AFA2-992AF13F608C Q26776345-98635055-973E-418C-BD50-BBBCB28366AB Q26823515-AC12990C-74B5-4EC8-B04A-1316971076EC Q27011298-1A3D1770-CD23-466F-B4E5-C226C6DDF299 Q33655849-31B70B9F-33FC-4FD2-A12F-56CC83279ADB Q33833475-A66ED64E-F04E-4B57-921C-86BDC37699E4 Q34044213-129DF1EC-9226-40FE-9BD6-A195F3F2D084 Q34046505-4D403EB2-69CD-43B2-8941-7C5AF3FB894A Q34248531-0D008B0C-028F-4C19-960F-D9604DF14474 Q34645898-60A8390A-4AB1-46BF-B1D4-57D80246577D Q35034010-008FA8AA-6E29-4BCA-A37D-CF0F988C87DE Q35506724-68902359-4A02-4808-9EFB-B3A739393865 Q35837949-88CD9399-D7D2-4A91-B2B2-9C3B5E7866C3 Q35892897-99197DCB-6EEC-4687-BD04-EB89067B6360 Q36470354-F276FBE0-CB44-45E1-8F9E-CAE07C748897 Q36855245-D2C53DBA-5E3F-4769-8856-10AE2F164298 Q37224420-403232CC-8624-436C-A596-50AED773AC30 Q37390525-0B61F7A0-0EC5-4002-8C22-AA4157F82E93 Q37581537-9CFC0D4A-905E-40B4-8B77-C15A777FFB37 Q37662065-F5BD25E1-0CEE-47AF-9114-303938D9D5AD Q38170496-1884D223-6E25-4BB2-9C76-C5522B5AF56C Q38290031-F01B5104-68D0-4928-B39C-D09E80153159 Q38623057-550B25D7-C1EE-41D8-B7CA-BED8ED3B74CD Q38673161-00CE778C-3A56-4996-B6C8-1F7EF27544B0 Q38754498-00016A1F-AEA9-4DF1-999E-95C4A66C1478 Q38874911-9F8D3D5B-F3B5-4D10-8915-F541B6E72F30 Q40973052-BB6D68C0-CDB5-4DAC-93FB-0971BBF06053 Q41619752-7A051F7B-A74A-4283-911C-F34AC846C5D4 Q42362802-602B31E4-CACA-4372-B1D7-9876BF4F77D4 Q46111623-3A8C3D7A-EABC-4D2E-8645-C34541E7B3F4 Q47201278-3797365B-9562-4FDB-BCC9-DD92D56B5704 Q47309343-C83C2704-EC19-4D5A-B77E-7DC155D08DD2 Q47566281-872C3089-2343-465C-9AC2-966A36EC054B Q48337005-2DACF806-B17A-41A0-95E2-DD606268052E Q55164226-01CBEDF5-2DC3-48D9-BB99-04F098A1D9A1 Q55378779-CB695855-0596-4FE1-99BE-254065E27D10 Q57823195-8C432428-D9EA-43DB-A7FC-6B27EF813D1E

P2860

Successful eradication of established peritoneal ovarian tumors in SCID-Beige mice following adoptive transfer of T cells genetically targeted to the MUC16 antigen.

http://www.wikidata.org/entity/Q34007762

description

2010 nî lūn-bûn

@nan

2010 թուականի Յուլիսին հրատարակուած գիտական յօդուած

@hyw

2010 թվականի հուլիսին հրատարակված գիտական հոդված

@hy

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

name

Successful eradication of esta ...... targeted to the MUC16 antigen.

@ast

Successful eradication of esta ...... targeted to the MUC16 antigen.

@en

Successful eradication of esta ...... targeted to the MUC16 antigen.

@nl

type

label

Successful eradication of esta ...... targeted to the MUC16 antigen.

@ast

Successful eradication of esta ...... targeted to the MUC16 antigen.

@en

Successful eradication of esta ...... targeted to the MUC16 antigen.

@nl

prefLabel

Successful eradication of esta ...... targeted to the MUC16 antigen.

@ast

Successful eradication of esta ...... targeted to the MUC16 antigen.

@en

Successful eradication of esta ...... targeted to the MUC16 antigen.

@nl

P1433

Q34007762-E5E9A054-7AE2-4F71-8B51-E2287E45DADA

P1476

Q34007762-281FD15D-5D2C-4662-817B-39696DF3ABE5

P2093

Q34007762-42920CC6-9322-4F26-9786-920CFCDD1695

Q34007762-88914208-1B64-4E69-AF5D-DB0106AEC6E1

Q34007762-9F9419D1-2386-46EA-AECF-92FE18E249EE

Q34007762-CDAF8B8E-DB65-446A-8896-8E787F8869D0

Q34007762-D95F2B8C-1DBD-4EF4-837E-A4997578EE6B

Q34007762-FA120F5F-4336-41B6-94D4-0968B2F23811

P2860

Q34007762-01C6813F-77DF-46E6-84A2-FA60275D2268

Q34007762-0FF6C2B4-0104-4828-B11C-6EF02AB35C23

Q34007762-139F1C91-0903-4444-AFDA-FA5A4C0B0403

Q34007762-15167D55-192B-4448-AF29-691247AA1297

Q34007762-18D04578-E513-4C27-997A-E41664C8F8FB

Q34007762-23CA1EB4-9AD8-4B6B-850F-51E3B3EDDFBD

Q34007762-2640FD71-DB74-4B8E-BC01-B4CBE3059FFF

Q34007762-27BC6D78-502C-464E-AFC9-E01FC884ABC4

Q34007762-2C45DCFC-060C-408B-B61F-C5787E32FB01

Q34007762-2F058AF6-B289-40B7-A2CB-F61E29742D6C

P304

Q34007762-51C01A6A-8546-4BDC-A21D-CC3F40F02994

P31

Q34007762-15C3B87D-D173-4029-BA96-BBDE705BA0C7

P356

Q34007762-9EDB5E0C-2780-4409-ADAE-8005072FFF69

P407

Q34007762-7AF75D74-6C7D-4DA4-BCB2-BC40D5DF5722

P433

Q34007762-61A927E8-6827-4062-BBEC-BF7E9B356438

P478

Q34007762-3E8EB7DF-B641-47D3-A553-031F9543A913

P50

Q34007762-C4176972-46F2-49AF-8432-690D0E43543F

P577

Q34007762-742A9E9F-B93D-4242-AFF7-F3FDB0F00BF9

P5875

Q34007762-301B11D6-76C9-4252-8DFF-30034B5FF70D

P698

Q34007762-CD0FAD56-2B26-4978-9ECC-38468AB0FFFD

P932

Q34007762-A5F6E036-0427-47F8-8BFD-77BA09C0DCA0

P356

1078-0432.CCR-10-0192

P1433

Clinical Cancer Research

P1476

Successful eradication of esta ...... targeted to the MUC16 antigen

@en

P2093

Alena A Chekmasova

http://www.w3.org/2001/XMLSchema#string

David R Spriggs

http://www.w3.org/2001/XMLSchema#string

Douglas A Levine

http://www.w3.org/2001/XMLSchema#string

Renier J Brentjens

http://www.w3.org/2001/XMLSchema#string

Thapi D Rao

http://www.w3.org/2001/XMLSchema#string

Yan Nikhamin

http://www.w3.org/2001/XMLSchema#string

P2860

Programmed cell death 1 ligand 1 and tumor-infiltrating CD8+ T lymphocytes are prognostic factors of human ovarian cancer

Antigen-specific immunotherapy of cervical and ovarian cancer

Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival

Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer

Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2

Virus-specific T cells engineered to coexpress tumor-specific receptors: persistence and antitumor activity in individuals with neuroblastoma

Gene-modified T cells for adoptive immunotherapy of renal cell cancer maintain transgene-specific immune functions in vivo.

More than 15 years of CA 125: what is known about the antigen, its structure and its function.

Chimeric NKG2D T cells require both T cell- and host-derived cytokine secretion and perforin expression to increase tumor antigen presentation and systemic immunity.

Cloning immunoglobulin variable domains for expression by the polymerase chain reaction

P304

3594-3606

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1158/1078-0432.CCR-10-0192

http://www.w3.org/2001/XMLSchema#string

P407

P433

14

http://www.w3.org/2001/XMLSchema#string

P478

16

http://www.w3.org/2001/XMLSchema#string

P50

P577

2010-07-13T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

45185268

http://www.w3.org/2001/XMLSchema#string

P698

20628030

http://www.w3.org/2001/XMLSchema#string

P932

2907178

http://www.w3.org/2001/XMLSchema#string